Literature DB >> 22575074

Sex differences in the Nociceptin/Orphanin FQ system in rat spinal cord following chronic morphine treatment.

Yong Zhang1, Courtney L Donica, Kelly M Standifer.   

Abstract

Nociceptin/Orphanin FQ (N/OFQ) appears to contribute to the development of morphine tolerance, as blockade of its actions will block or reverse the process. To better understand the contribution of N/OFQ to the development of morphine tolerance, this study examined the effect of chronic morphine treatment on levels of N/OFQ and levels and activity of the N/OFQ peptide (NOP) receptor in spinal cord (SC) from male and female rats. Both male and female Wistar rats showed less responsiveness to morphine after subcutaneous injection of escalating doses of morphine (10, 20, 40, 60 and 80 mg/kg, respectively) twice daily for five consecutive days. Male rats were more tolerant to the antinociceptive actions of morphine than females. The N/OFQ content of SC extracts was higher in females than in males, regardless of treatment; following chronic morphine treatment the difference in N/OFQ levels between males and females was more pronounced. N/OFQ content in cerebrospinal fluid (CSF) was reduced 40% in male and 16% in female rats with chronic morphine exposure, but increased in periaqueductal grey of both sexes. Chronic morphine treatment increased NOP receptor levels 173% in males and 137% in females, while decreasing affinity in both. Chronic morphine increased the efficacy of N/OFQ-stimulated [³⁵S]GTPγS binding to SC membranes from male rats, consistent with increased receptor levels. Taken together, these findings demonstrate sex differences in N/OFQ-NOP receptor expression and NOP receptor activity following chronic morphine treatment. They also suggest interplay between endogenous N/OFQ and chronic morphine treatment that results in nociceptive modulation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22575074      PMCID: PMC5009626          DOI: 10.1016/j.neuropharm.2012.04.028

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  55 in total

1.  Importance of sex and relative efficacy at the mu opioid receptor in the development of tolerance and cross-tolerance to the antinociceptive effects of opioids.

Authors:  A C Barrett; C D Cook; J M Terner; R M Craft; M J Picker
Journal:  Psychopharmacology (Berl)       Date:  2001-11       Impact factor: 4.530

2.  Nociceptin/orphanin FQ knockout mice display up-regulation of the opioid receptor-like 1 receptor and alterations in opioid receptor expression in the brain.

Authors:  S Clarke; Z Chen; M-S Hsu; R G Hill; J E Pintar; I Kitchen
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

3.  Functional studies using antibodies against orphanin FQ/nociceptin.

Authors:  J H Tian; J S Han
Journal:  Peptides       Date:  2000-07       Impact factor: 3.750

4.  Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance.

Authors:  Shinjae Chung; Sigrun Pohl; Joanne Zeng; Olivier Civelli; Rainer K Reinscheid
Journal:  J Pharmacol Exp Ther       Date:  2006-04-04       Impact factor: 4.030

5.  Nociceptin levels in the cerebrospinal fluid of chronic pain patients with or without intrathecal administration of morphine.

Authors:  William Raffaeli; Boaz Gedaliahu Samolsky Dekel; Daniela Landuzzi; Alessandro Caminiti; Donatella Righetti; Marco Balestri; Francesco Montanari; Patrizia Romualdi; Sanzio Candeletti
Journal:  J Pain Symptom Manage       Date:  2006-10       Impact factor: 3.612

6.  Spinal analgesic activity of orphanin FQ/nociceptin and its fragments.

Authors:  M A King; G C Rossi; A H Chang; L Williams; G W Pasternak
Journal:  Neurosci Lett       Date:  1997-02-21       Impact factor: 3.046

7.  Conditioned opioid withdrawal decreases nociceptin/orphanin FQ levels in the frontal cortex and olfactory tubercle.

Authors:  John R Walker; Lars Terenius; George F Koob
Journal:  Neuropsychopharmacology       Date:  2002-08       Impact factor: 7.853

Review 8.  Sex-specific responses to opiates: animal and human studies.

Authors:  Albert Dahan; Benjamin Kest; Amanda R Waxman; Elise Sarton
Journal:  Anesth Analg       Date:  2008-07       Impact factor: 5.108

9.  Cloning and functional characterization through antisense mapping of a kappa 3-related opioid receptor.

Authors:  Y X Pan; J Cheng; J Xu; G Rossi; E Jacobson; J Ryan-Moro; A I Brooks; G E Dean; K M Standifer; G W Pasternak
Journal:  Mol Pharmacol       Date:  1995-06       Impact factor: 4.436

10.  ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization.

Authors:  C Mollereau; M Parmentier; P Mailleux; J L Butour; C Moisand; P Chalon; D Caput; G Vassart; J C Meunier
Journal:  FEBS Lett       Date:  1994-03-14       Impact factor: 4.124

View more
  4 in total

1.  Spinal Opioid Tolerance Depends upon Platelet-Derived Growth Factor Receptor-β Signaling, Not μ-Opioid Receptor Internalization.

Authors:  S Puig; K E Barker; S R Szott; P T Kann; J S Morris; H B Gutstein
Journal:  Mol Pharmacol       Date:  2020-07-28       Impact factor: 4.436

Review 2.  Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ.

Authors:  Courtney L Donica; Hibah O Awwad; Deepak R Thakker; Kelly M Standifer
Journal:  Mol Pharmacol       Date:  2013-02-08       Impact factor: 4.436

3.  Involvement of the nociceptin opioid peptide receptor in morphine-induced antinociception, tolerance and physical dependence in female mice.

Authors:  Xiao-Qing Hao; Zhi-Yuan Wang; Jian-Min Chen; Ning Wu; Jin Li
Journal:  Metab Brain Dis       Date:  2021-09-16       Impact factor: 3.584

4.  Beneficial effects of co-treatment with dextromethorphan on prenatally methadone-exposed offspring.

Authors:  Yao-Chang Chiang; Li-Ci Ye; Kuei-Ying Hsu; Chien-Wei Liao; Tsai-Wei Hung; Wan-Jou Lo; Ing-Kang Ho; Pao-Luh Tao
Journal:  J Biomed Sci       Date:  2015-03-20       Impact factor: 8.410

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.